1.64

1.23% +0.02

Altamira Therapeutics Ltd (CYTO)

Overview News Price History Why CYTO Down? Discussions Forecast Stock Split

Altamira Therapeutics Ltd stock is currently priced at $1.64, with a 24-hour trading volume of 29,769. It has seen a +1.23% increased in the last 24 hours and a -15.46% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.62 pivot point. If it approaches the $1.67 resistance level, significant changes may occur.

Previous Close:

$1.62

Open:

$1.65

24h Volume:

29,769

Market Cap:

$3.67M

Revenue:

$132.70K

Net Income/Loss:

$-25.04M

P/E Ratio:

-0.0794

EPS:

-20.6616

Net Cash Flow:

1W Performance:

-2.96%

1M Performance:

-15.46%

6M Performance:

-45.33%

1Y Performance:

-90.41%

1D Range:

$1.60

$1.66

52W Range:

$1.35

$28.40

Altamira Therapeutics Ltd Stock (CYTO) Company Profile

Name

Altamira Therapeutics Ltd

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

441-295-5950

Address

Clarendon House, 2 Church Street, Hamilton

Employee

Twitter

Next Earnings Date

2024-05-16

Latest SEC Filings

CYTO's Discussions on Twitter

Altamira Therapeutics Ltd Stock (CYTO) Latest News

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

GlobeNewswire Inc.

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

GlobeNewswire Inc.

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

GlobeNewswire Inc.

Nasdaq Turns Higher; Akanda Shares Plunge

Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Crude Oil Moves Higher; US New Home Sales Fall In February

Benzinga

Altamira Therapeutics Ltd Stock (CYTO) Financials Data

Altamira Therapeutics Ltd (CYTO) Revenue 2024

CYTO reported a revenue (TTM) of $132.70 thousand for the quarter ending June 30, 2023.

Altamira Therapeutics Ltd (CYTO) Net Income 2024

CYTO net income (TTM) was -$25.04 million for the quarter ending June 30, 2023, a -84.82% decrease year-over-year.

Altamira Therapeutics Ltd (CYTO) Earnings per Share 2024

CYTO earnings per share (TTM) was -$413.23 for the quarter ending June 30, 2023, a +23.58% growth year-over-year.

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.